Significance: Our data strongly argue against the widely held belief that neurogenin3 is a marker of beta cell neogenesis in the adult pancreas, especially from duct cells.
Summary:
It remains controversial whether adult pancreatic ducts harbor facultative beta cell progenitors. Since neurogenin3 (Ngn3) is a key determinant of pancreatic endocrine cell neogenesis during embryogenesis, many studies have also relied upon Ngn3 expression as evidence of beta cell neogenesis in adults. Recently, however, Ngn3 as a marker of adult beta cell neogenesis has been called into question by reports of Ngn3 expression in fully-developed beta cells. Nevertheless, direct evidence as to whether Ngn3 activation in adult pancreatic duct cells may lead to duct-to-beta cell transdifferentiation is lacking. Here we studied two models of Ngn3 activation in adult pancreatic duct cells (low-dose alloxan treatment and pancreatic duct ligation) and lineage-traced Ngn3-activated duct cells by labeling them through intraductal infusion with a cell-tagging dye, CFDA-SE. No dye-labeled beta cells were found during the follow-up in either model, suggesting that activation of Ngn3 in duct cells is not sufficient to direct their transdifferentiation into beta cells. Therefore, Ngn3 activation in duct cells is not a signature for adult beta cell neogenesis.
Introduction:
The shortage of donor pancreases is a major obstacle to the widespread application of islet transplantation to treat diabetic patients(1,2). Therefore, great efforts have been made to identify alternative sources of insulin-producing cells (3) . Previous studies have suggested that cell replication is the only mechanism for beta cell expansion in adults (4) (5) (6) (7) (8) (9) . However, researchers continue to seek evidence of beta cell neogenesis (10) (11) (12) (13) since adult beta cells normally show very slow proliferation (14) (15) (16) (17) (18) (19) (20) , and may quickly undergo senescence or apoptosis if forced into the cell cycle(21).
Adult pancreatic duct cells have been extensively studied for their potential to generate functional beta cells, since embryonic pancreatic ductal structures clearly harbor endocrine precursors(22-24). Recently, lineage tracing studies have been used to evaluate the possible conversion of duct cells into beta cells postnatally, but with conflicting results (25-31). In particular, in the pancreatic duct ligation (PDL) model, neurogenin3
(Ngn3), a pancreatic endocrine-determining transcription factor during embryonic development (32-34), was reported to be activated in the duct cells of the ligated pancreas(35). Since Ngn3 has long been regarded as a marker of beta cell neogenesis(36,37), and since beta cell proliferation after PDL remains at a low level(35), it was logically concluded that the reported doubling of beta cell mass within one week of PDL is due to beta cell neogenesis from Ngn3 + duct cells(35).
Notably, both this doubling of beta cell mass and the proposed duct-to-beta cell transdifferentiation in the PDL model have been challenged by subsequent studies (8, (25) (26) (27) (28) 30, 31, 38) . Tissue edema and remodeling after PDL have been sited Page 3 of 15 as potential reasons for over-estimation of the increase in beta cell mass (27, 31, 38) . On the other hand, independent reports have shown that Ngn3 is also expressed in adult beta cells, and can be up-regulated after PDL (8, 27, (39) (40) (41) . However, direct evidence that Ngn3 activation in adult pancreatic duct cells may lead to neogenesis of beta cells is lacking(42).
Here, we examined the fate of Ngn3-activated duct cells in the adult pancreas in two models, low-dose alloxan (ALX) treatment and PDL. We found that Ngn3 expression was activated in duct cells in both models. To lineage-trace these Ngn3-activated duct cells, we used an intraductal infusion system to efficiently and specifically label pancreatic duct cells with CFDA-SE (carboxyfluorescein diacetate, succinimidyl ester), a dye that passively enters the duct cells, and then is retained within the cells. No dye-labeled beta cells were found in either model, suggesting Ngn3 activation in duct cells is not sufficient to direct their transdifferentiation into beta cells.
Experimental Procedures Mouse and cell manipulation
All mouse experiments were approved by the Animal Research and Care Committee at the Children's Hospital of Pittsburgh and the University of Pittsburgh IACUC.
Bacterial-artificial-chromosome (BAC) transgenic Elastase promoter CreERT reporter (Ela-CreERT) mouse was generated and kindly provided by Dr. Craig Logsdon (University of Texas)(43). C57/6, Rosa26CAGTomato (Tomato), BAC transgenic Ngn3 promoter Cre reporter (Ngn3-Cre)(44), BAC transgenic mouse insulin promoter GFP reporter (MIP-GFP) and ROSAmTmG (mTmG)(8) mice were all purchased from Jackson Lab, and all have a C57/6 background. Male Ngn3-Cre and female mTmG mice were crossed to generate the Ngn3-Cre; mTmG mice. Male Ela-CreERT and female Tomato mice were crossed to generate Ela-CreERT; Tomato mice. Tamoxifen (Sigma) solution (20mg/ml) was freshly prepared the day prior to each injection, by dissolving in filter-sterilized corn oil. To induce tomato expression in acinar cells, 4 weeks before analysis/operation, Ela-CreERT; Tomato mice were given a single intraperitoneal injection of 1mg tamoxifen (50 µl) or corn oil vehicle (control). 99.6±2.1% acinar cells were found labeled without detectable non-specific labeling of other cell types. Only mice that were heterozygous for both Cre (ERT) and mTmG were used for our experiments.
All experiments used 8-week-old males.
The beta-cell toxin alloxan (ALX) was injected into mice via the dorsal tail vein with a dosage of 65 mg/kg or 30mg/kg. Blood glucose measurements of mice were performed after a 2 hour fasting period. PDL was performed and quality controlled (morphology, upregulation in Ngn3 transcript in ligated tail vs unligated head of pancreas) as described by us previously (8, 45) .
CFDA-SE (Invitrogen) was prepared according to manufacturer's instruction. Pancreatic intraductal CFDA-SE infusion was performed after anesthetizing the animals. Briefly, the duodenum was isolated to expose the common bile duct, after which a microclamp (Roboz, RS-7439) was placed on the common bile duct above the branching of the pancreatic duct. A 31-gauge blunt-ended catheter (World Precision Instruments) was then put into the common bile duct through the sphincter of Oddi in the duodenum, which was then clamped with another microclamp (Roboz, 
Laser-capture microdissection (LCM)
Mouse pancreas was harvested, snap frozen, sectioned and mounted on RNAse-free membrane-coated microscopy slides (Molecular Machines and Industries, MMI) as described previously(46), followed by 30 minutes' incubation with DBA to label the duct cells with green fluorescence.
RNA isolation and RT-qPCR
RNA extraction and RT-qPCR have been described previously (8, 45, 46) . Primers were all purchased from Qiagen. They are
Cd31 (QT01052044). RT-qPCR values were normalized against CycloA, which proved to be stable across the samples.
Immunohistochemistry
All pancreas samples were fixed in zinc (BD) for 4 hours followed by an additional 2 hours' fixation in 4% formaldehyde, then cryo-protected in 30% sucrose overnight before freezing. mT and mG were detected by direct fluorescence. Since Ngn3 activation has been reported after PDL(35) and after beta-cell-specific toxin treatment(48,49), we examined the pancreas from these Ngn3-Cre; mTmG mice after treatment with ALX or after PDL. Because Ngn3 activation after beta-cell-toxin treatment has not been reported consistently(48,49), we suspected that the dosage of the toxin may affect Ngn3 activation. Thus, we tested the effect of two different ALX doses. A high-dose ALX (65mg/kg) was sufficient to induce sustained hyperglycemia by destroying more than 90% of the beta cells in mice with a C57/6 background. Although neither hyperglycemia nor significantly altered beta cell mass was detected after a low-dose ALX (30mg/kg) treatment ( Fig. 1B and data not shown), we indeed found significant changes in transcripts of certain genes (e.g., upregulation of Ngn3 and FoxO1 mRNA, downregulation of Glut2 mRNA) in beta cells, suggesting that the beta cells were injured by low-dose ALX and may then undergo some degree of de-differentiation(50-55) (data not shown). On the other hand, by analysis of stained sections, we found a roughly 10-fold increase in the fraction of mG + duct cells in the pancreas of Ngn3-Cre; mTmG mice either after 30mg/kg ALX treatment (59.5±2.3%), or after PDL (83.4±3.6%), but not after high-dose ALX (65mg/kg) treatment (7.6±0.8%), compared with untreated controls (6.4±0.5%). Similarly, we found a significant increase in the fraction of mG + acinar cells in the pancreas of cells (representing Ngn3-inactivated duct cells) from Ngn3-Cre; mTmG mice 1 week after either low-dose ALX or PDL, and also analyzed transcripts for Ck19 and Sox9, which are predominantly expressed by duct cells in the adult pancreas. We found that both transcripts were significantly downregulated in Ngn3-activated duct cells after PDL, but the decreases after low-dose ALX did not reach significance (Fig. 3) . These data suggest that PDL may be a more potent trigger for duct cell phenotypic changes, consistent with the higher levels of Ngn3 transcript after PDL than after low-dose ALX (Fig. 2D) , as well as the higher fraction of Ngn3-lineage tagged duct cells after PDL.
Ngn3-activated duct cells do not produce endocrine hormones
Next we examined whether these Ngn3-activated duct cells may start to produce endocrine hormones, as appears to occur in Ngn3-activated progenitor cells during embryonic pancreatic development(32-34). Since we found this up-regulation of Ngn3 occurs as early as 3 days after either low-dose ALX or after PDL, we expected to see hormone-positive duct cells derived from Ngn3-activated duct cells (hormone + mG + duct cells in Ngn3-Cre; mTmG mice) by 1 week after ALX or PDL if the Ngn3-activated duct cells do indeed differentiate into endocrine cells. We did not find an increase in hormone + mG + duct cells with either treatment (Fig. 4) , suggesting that Ngn3 activation in adult duct cells does not lead to duct-to-endocrine cell transdifferentiation.
Long-term tracking of pancreatic duct cells with CFDA-SE
Since the above experiments could not exclude the possibility that Ngn3-activated duct cells may subsequently migrate out of the ducts prior to analysis, we further examined whether Ngn3-activated duct cells could form endocrine cells outside of the ducts over a relatively long time period. To track Ngn3-activated duct cells, we applied a novel intraductal infusion method to efficiently and specifically label pancreatic duct cells with CFDA-SE, a dye that passively enters the cells and then is retained within the cells (56) . At a speed of 1μl/min, 30μl of 10μM CFDA-SE was infused into the pancreatic duct through a fine blunt-ended catheter, leading to efficient labeling of the majority of ducts throughout the entire pancreas (Fig. 5A ).
One week after infusion, the pancreatic ducts are readily visualized grossly (Fig. 5B) or by whole-mount imaging (Fig. 5C ).
The fluorescence of individual CFDA-SE-labeled cells should reduce by half after each cell division. Thus, we evaluated the maximal number of cell divisions that would still allow the cellular fluorescence to remain detectable. NIH 3T3 cells (with a 20 hours' doubling time) were incubated with different concentration of CFDA-SE for 30 minutes, after which the cells were extensively washed and their fluorescence level compared with sorted green duct cells (30μl of 10μM CFDA-SE infused at a speed of 1μl/min, taking 30 minutes) from the pancreatic digests by FACS. We found that 3T3 cells incubated with 8μM CFDA-SE had similar fluorescence intensity as the in vivo freshly-labeled duct cells. The fluorescence intensity of these 3T3 cells was examined after serial cell divisions, with cell counting to confirm cell divisions. Fluorescence of the labeled cells was still detectable after 7 cell divisions, but essentially not after 8 divisions (Fig. 5D ). These results suggest that the labeled duct cells in our intraductal infusion system could remain detectable for up to 7 divisions.
To exclude the possibility that CFDA-SE infusion itself may affect Ngn3 activation in duct cells, DBA + (cy5) duct cells were isolated 1 week after low-dose ALX treatment, or after PDL, with or without CFDA-SE infusion. No significant difference in Ngn3 transcripts in duct cells was detected after either low-dose ALX treatment, or after PDL, with CFDA-SE infusion (Fig. 5E ), suggesting that CFDA-SE infusion did not change Ngn3 activation in duct cells. Quantification of CFDA-SE labeling efficiency on sections of the pancreas at 3 days (the earliest time point when Ngn3-Cre; mTmG duct cells were labeled after PDL or low-dose ALX), 1 week and 4 weeks was performed and showed no significant differences, suggesting that CFDA-SE does not selectively label cell fractions with different proliferative potentials. We found that 45.6±4.8% of all duct cells (CK19  + ) were successfully labeled with CFDA-SE (Fig. 6A) . Non-duct cell labeling was not seen. We further determined that the labeling efficiency of the main duct cells was 78.3±6.7%, of intralobular duct cells was 28.4±3.7%, and of centroacinar cells was 2.1±0.2%.
Ngn3-activated duct cells do not become endocrine cells
One week after CFDA-SE intraductal labeling, the mice received either 30mg/kg ALX or PDL treatment. The mice were sacrificed after another 4 weeks and assessed for any possible contribution of labeled duct cells to the endocrine cell population. No dye-labeled beta cells (Fig.  6B, upper panel) or other endocrine cells were found after 30mg/kg ALX. Moreover, we did not find dye-labeled beta cells in either larger islets (Fig. 6B, middle panel) or small beta-cell clusters (Fig. 6B, lower  panel) after PDL. The duct-like structures after PDL were extensively labeled with the dye (Fig. 6B, middle and lower panels) , suggesting that these structures were mainly derived from the pre-existing duct network, consistent with a recent report(30). Also, these data suggest that the number of proliferation rounds in the duct cells did not exceed our CFDA-SE detection limitation (7 cycles) within 4 weeks. To further confirm this possibility, CFDA-SE signal intensities of labeled duct cells were compared by FACS, 1 day and 4 weeks after combined CFDA-SE infusion and PDL. Our data show CFDA-SE intensity significantly decreased after 4 weeks, but still remained readily detectable (Fig. 6C) . Also, since there was a clear separation between the CFDA-SE-labeled fluorescent population of cells and the unlabeled population (Fig. 6C,  arrow) , we concluded that duct cells proliferate less than 7 cycles during the 4 weeks period (Fig. 5D) . These data thus demonstrate that the majority, if not all CFDA-SE labeled duct cells remain detectable after 4 weeks' follow-up. The CFDA-SE labeling intensity among individual duct cells became much more variable 4 weeks after labeling and PDL, suggesting a differential proliferative capacity among different duct cells after PDL (Fig. 6C ).
Acinar cells do not become endocrine cells after PDL
While not the primary focus of our study, we did also look at whether some acinar cells in the ligated tail pancreas after PDL may transdifferentiate into endocrine cells. Here, we used Ela-CreERT; Tomato mice to lineage trace acinar cells. In this model, one low dose (1mg) of tamoxifen injection successfully labeled 99.6±2.1% acinar cells (Fig.  7A ). Tamoxifen-independent labeling of acinar cells should not confound our data interpretation, since we did not see cells other than acinar cells labeled. We did not find evidence of substantial contribution of acinar cells to beta cells 4 weeks after either 30mg/kg ALX (data not shown) or PDL (Fig. 7B) , consistent with previous reports(57,58). We did not perform longer follow-up(30), since long-term lineage tracing may substantially suffer from misleading labeling of pre-existing beta cells due to leakage of CreER into the nuclei of beta cells (8) .
Discussion
Activation of Ngn3 is a signature for pancreatic endocrine cell neogenesis during embryogenesis(32-34). However, whether Ngn3 activation in the adult pancreas also indicates endocrine cell neogenesis has been debated, and the question relates closely to the central issue of the possible existence of beta cell progenitors in the adult pancreas. Although recent reports revealed that adult beta cells express a low level of Ngn3(27,39-41), it remains controversial as to whether Ngn3 activation in adult pancreatic duct cells may be an indicator of duct-to-endocrine neogenesis (8,25-29,31,42).
Here we examined this question in two models of Ngn3 activation in adult pancreatic duct cells (low-dose ALX and PDL). Of note, upregulation of Ngn3 in duct cells by low-dose ALX may be related to a sub-lethal injury of the beta cells, since the injured beta cells may release cytokines/factors to affect nearby duct cells in a paracrine way. The differential Ngn3 activation in duct cells by different doses of ALX could result from the different phenotype of injured (not dead) beta cells (in 30mg/kg ALX) versus destroyed (dead) beta cells (in 65mg/kg ALX). This question is not the primary focus of our study, and here we focused our analysis on Ngn3 transcripts from purified duct cells. There is also significant controversy regarding whether there is a significant change in beta cell mass after PDL(25,27,31,35,38). We did not perform a beta cell mass analysis here, since beta cell mass quantification after PDL is difficult, due to severe tissue edema and organ remodeling(27,31,38).
Previous analyses of duct cell lineages have used a tamoxifen-sensitive Cre-labeling system(25-29,42). However, RIP-CreERT mice(4) were reported to have either prolonged tamoxifen-induced cre activation(59), or pre-labeling of beta cells in young (60) or aged mice (58) , as well as cell-type specific apoptosis(61). Other CreERT strains could potentially suffer from similar flaws related to specificity and sensitivity. Here we used either a straight Cre (no ERT) or a novel non-genetic method to label duct cells (intraductal infusion of CFDA-SE). Once the lipid soluble CFDA-SE enters the cytoplasm of duct cells, intracellular esterases remove the acetate groups of CFDA-SE and convert the molecule to the non-membrane permeable fluorescent ester (CFSE) (56) . Due to this covalent coupling reaction, fluorescent CFSE is retained within cells for long periods, and is not transferred to adjacent cells (56) . We found that the optimal labeling of duct cells, with no detectable non-specific non-ductal labeling, is achieved with the infusion of 30μl of 10μM CFDA-SE at a speed of 1μl/min. Of note, a faster infusion or higher dose of CFDA-SE may result in labeling of some periductal cells, perhaps due to CFDA-SE leakage out of the ducts under higher pressure. Thus, since specificity is our highest priority, we were unable to increase dosing to further improve labeling efficiency. Importantly, CFDA-SE labeling seems to be a robust system since we showed that the labeled cells remain detectable after at least 7 doublings.
Using either this dye-labeling or a Ngn3-Cre labeling system, we found that adult Ngn3-activated duct cells do not give rise to beta cells or other endocrine cells, consistent with a previous report (58) . Thus, Ngn3 may not be an ideal marker for the identification of beta cell progenitors in adults.
To summarize our findings, although Ngn3 had been previously regarded as a marker of endocrine cell neogenesis from pancreatic ducts in adults(36,37), our study provides direct evidence othewise. Demonstration of Ngn3 activation alone in duct cells is not sufficient to show adult beta cell neogenesis. Transcripts of two markers predominantly expressed by duct cells in the adult pancreas, Ck19 and Sox9, were analyzed, showing that both were downregulated in Ngn3-activated duct cells after PDL, but their change in Ngn3-activated duct cells after low-dose ALX did not reach significance. 
